عرض بسيط للتسجيلة

المؤلفAbushanab, Dina
المؤلفNasr, Ziad G.
المؤلفAl-Badriyeh, Daoud
تاريخ الإتاحة2023-07-06T11:34:45Z
تاريخ النشر2022-11-01
اسم المنشورAntibiotics
المعرّفhttp://dx.doi.org/10.3390/antibiotics11111630
الاقتباسAbushanab, D., Nasr, Z. G., & Al-Badriyeh, D. (2022). Efficacy and Safety of Colistin versus Tigecycline for Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Pathogens—A Meta-Analysis. Antibiotics, 11(11), 1630.
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149468387&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/45131
الملخصBackground: We intended to compare the efficacy and safety outcomes of colistin versus tigecycline as monotherapy or combination therapy against multi-drug resistant (MDR) and extensively drug-resistant (XDR) pathogens. Methods: A search was conducted in PubMed, Cochrane CENTRAL, EMBASE, and in the grey literature (i.e., ClinicalTrials.gov and Google Scholar) up to May 2021. Outcomes were clinical response, mortality, infection recurrence, and renal and hepatic toxicity. We pooled odd ratios (OR) using heterogeneity-guided random or fixed models at a statistical significance of p < 0.05. Results: Fourteen observational studies involving 1163 MDR/XDR pathogens, receiving tigecycline versus colistin monotherapy or combination, were included. Base-case analyses revealed insignificant differences in the clinical response, reinfection, and hepatic impairment. The 30-day mortality was significantly relatively reduced with tigecycline monotherapy (OR = 0.35, 95% CI 0.16–0.75, p = 0.007). The colistin monotherapy significantly relatively reduced in-hospital mortality (OR = 2.27, 95%CI 1.24–4.16, p = 0.008). Renal impairment rates were lower with tigecycline monotherapy or in combination, and were lower with monotherapy versus colistin-tigecycline combination. Low-risk of bias and moderate/high evidence quality were associated with all studies. Conclusions: Within the limitations of this study, it can be concluded that there were no statistically significant differences in main efficacy outcomes between colistin and tigecycline monotherapies or combinations against MDR/XDR infections, except for lower rates of 30-day mortality with tigecycline and in-hospital mortality with colistin. Tigecycline was associated with favourable renal toxicity outcomes.
راعي المشروعPublication fees funding was provided by the Qatar National Library, Qatar.
اللغةen
الناشرMultidisciplinary Digital Publishing Institute (MDPI)
الموضوعcolistin
extensively drug-resistant
infection
multi-drug resistant
tigecycline
العنوانEfficacy and Safety of Colistin versus Tigecycline for Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Pathogens—A Meta-Analysis
النوعArticle
رقم العدد11
رقم المجلد11
ESSN2079-6382
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة